Phase-III Clinical Trial of a Ruxolitinib Drug for Covid-19 Treatment Has Begun

First approved in 2011 for myelofibrosis and later in 2014 for polycythemia vera, and approved by the US Food and Drug Administration (FDA) in 2019 for acute graft-versus-host disease, ruxolitinib (Jakafi) is now being tested to treat the cytokine storm caused by Covid-19 infection due to the novel coronavirus in a phase-III clinical trial, as has been announced.
Ruxolitinib is one of the few hemato-oncology drugs that work by affecting epigenetic mechanisms. Ruxolitinib acts by blocking the function of molecules called JAK1 and JAK2 (Janus kinases), which are involved in blood cell production and the immune response. Immune system suppression is one of its properties.
A cytokine storm is an excessive immune reaction to a viral infection and can cause serious complications such as non-microbial pneumonia and acute respiratory distress syndrome (ARDS). Hyperinflammation is another name for this.
RUXCOVID is a global, randomized, double-blind, placebo-controlled phase-III trial that will assess the safety and efficacy of ruxolitinib in approximately 400 Covid-19 patients older than 12 worldwide.
RUXCOVID is funded by Incyte in the United States and Novartis outside the United States. In early April, Incyte and Novartis announced their plans to conduct the phase-III trial.
We know that approximately 20% of patients with a confirmed Covid-10 diagnosis need hospitalization because of severe disease, and approximately 6% require intensive care.
There is an unprecedented medical need for treatments that prevent or reduce complications associated with severe Covid-19, to improve patient outcomes and alleviate the overwhelming pressure on the global healthcare system.
The outcome to be measured in this phase-III trial is the primary endpoint, the proportion of participants who have died, required mechanical ventilation or needed an intensive care unit (ICU) because of respiratory failure by day 29.
Secondary endpoints include efficacy assessments such as clinical status, in-hospital outcomes, changes in the National Early Warning Score (NEWS2) and the SpO2 / FiO2 ratio, the proportion of patients who no longer need oxygen therapy, and safety.
Patients randomly assigned to two arms will receive standard supportive care plus placebo or oral 5mg ruxolitinib tablets twice daily in combination with standard treatments for a total of 14 days.
After 14 days of treatment, participants may receive the study treatment for another 14 days if clinical signs do not worsen and the potential benefit outweighs the potential risks. Patients will be followed for a total of 29 days.
Incyte noted that the current commercial and clinical supply of ruxolitinib in the United States is sufficient to meet the needs of patients in the country for approved indications and clinical trials. The company is also increasing manufacturing efforts to meet anticipated supply needs for Covid-19 studies. Ruxolitinib for Covid-19 is also being provided under the US Expanded Access Program (EAP) to eligible patients who cannot participate in clinical trials.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.